These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 34478750)

  • 1. Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2.
    Kamat S; Kumari M; Jayabaskaran C
    J Control Release; 2021 Oct; 338():813-836. PubMed ID: 34478750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nano-Enabled Antivirals for Overcoming Antibody Escaped Mutations Based SARS-CoV-2 Waves.
    Rahman A; Roy KJ; Deb GK; Ha T; Rahman S; Aktar MK; Ali MI; Kafi MA; Choi JW
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicine for the SARS-CoV-2: State-of-the-Art and Future Prospects.
    Varahachalam SP; Lahooti B; Chamaneh M; Bagchi S; Chhibber T; Morris K; Bolanos JF; Kim NY; Kaushik A
    Int J Nanomedicine; 2021; 16():539-560. PubMed ID: 33519200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic.
    Weiss C; Carriere M; Fusco L; Capua I; Regla-Nava JA; Pasquali M; Scott JA; Vitale F; Unal MA; Mattevi C; Bedognetti D; Merkoçi A; Tasciotti E; Yilmazer A; Gogotsi Y; Stellacci F; Delogu LG
    ACS Nano; 2020 Jun; 14(6):6383-6406. PubMed ID: 32519842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanotechnology-Based Strategies for the Management of COVID-19: Recent Developments and Challenges.
    Singh R; Behera M; Kumari N; Kumar S; Rajput VD; Minkina TM; Adnan M; Siddiqui AJ; Kumar N
    Curr Pharm Des; 2021; 27(41):4197-4211. PubMed ID: 34459371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanotechnology based solutions to combat zoonotic viruses with special attention to SARS, MERS, and COVID 19: Detection, protection and medication.
    Ramakrishnan SG; Robert B; Salim A; Ananthan P; Sivaramakrishnan M; Subramaniam S; Natesan S; Suresh R; Rajeshkumar G; Maran JP; Al-Dhabi NA; Karuppiah P; Valan Arasu M
    Microb Pathog; 2021 Oct; 159():105133. PubMed ID: 34390768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
    Milane L; Amiji M
    Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments.
    Mahmud N; Anik MI; Hossain MK; Khan MI; Uddin S; Ashrafuzzaman M; Rahaman MM
    ACS Appl Bio Mater; 2022 Jun; 5(6):2431-2460. PubMed ID: 35583460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanotechnology: an emerging approach to combat COVID-19.
    Chintagunta AD; M SK; Nalluru S; N S SK
    Emergent Mater; 2021; 4(1):119-130. PubMed ID: 33615141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights from nanotechnology in SARS-CoV-2 detection, treatment strategy, and prevention.
    Solanki R; Shankar A; Modi U; Patel S
    Mater Today Chem; 2023 Apr; 29():101478. PubMed ID: 36950312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-Generation Vaccines: Nanovaccines in the Fight against SARS-CoV-2 Virus and beyond SARS-CoV-2.
    Mufamadi MS; Ngoepe MP; Nobela O; Maluleke N; Phorah B; Methula B; Maseko T; Masebe DI; Mufhandu HT; Katata-Seru LM
    Biomed Res Int; 2023; 2023():4588659. PubMed ID: 37181817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Success of nano-vaccines against COVID-19: a transformation in nanomedicine.
    Sarangi MK; Padhi S; Rath G; Nanda SS; Yi DK
    Expert Rev Vaccines; 2022 Dec; 21(12):1739-1761. PubMed ID: 36384360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aptamers as promising nanotheranostic tools in the COVID-19 pandemic era.
    Dzuvor CKO; Tettey EL; Danquah MK
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 May; 14(3):e1785. PubMed ID: 35238490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilizing nanozymes for combating COVID-19: advancements in diagnostics, treatments, and preventative measures.
    Wang J; Xie Q; Song H; Chen X; Zhang X; Zhao X; Hao Y; Zhang Y; Li H; Li N; Fan K; Wang X
    J Nanobiotechnology; 2023 Jun; 21(1):200. PubMed ID: 37344839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation, Device, and Clinical Factors Influencing the Targeted Delivery of COVID-19 Vaccines to the Lungs.
    Mossadeq S; Shah R; Shah V; Bagul M
    AAPS PharmSciTech; 2022 Nov; 24(1):2. PubMed ID: 36416999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanotechnologies for the Diagnosis and Treatment of SARS-CoV-2 and Its Variants.
    Park E; Choi SY; Kim J; Hildebrandt N; Lee JS; Nam JM
    Small Methods; 2023 Jul; 7(7):e2300034. PubMed ID: 37189215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
    Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies.
    Hasanzadeh A; Alamdaran M; Ahmadi S; Nourizadeh H; Bagherzadeh MA; Mofazzal Jahromi MA; Simon P; Karimi M; Hamblin MR
    J Control Release; 2021 Aug; 336():354-374. PubMed ID: 34175366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.